DENTSPLY SIRONA (XRAY) Earns “Hold” Rating from HC Wainwright

DENTSPLY SIRONA (NASDAQ:XRAY)‘s stock had its “hold” rating restated by equities researchers at HC Wainwright in a report issued on Thursday. They currently have a $68.00 price objective on the medical instruments supplier’s stock. HC Wainwright’s price objective suggests a potential upside of 8.54% from the company’s previous close.

XRAY has been the subject of a number of other reports. Deutsche Bank started coverage on shares of DENTSPLY SIRONA in a research note on Friday, December 8th. They set a “buy” rating and a $81.00 price objective for the company. Zacks Investment Research upgraded shares of DENTSPLY SIRONA from a “sell” rating to a “hold” rating in a research note on Friday, October 20th. BidaskClub lowered shares of DENTSPLY SIRONA from a “strong-buy” rating to a “buy” rating in a research note on Saturday, December 2nd. Cleveland Research lowered shares of DENTSPLY SIRONA from a “buy” rating to a “neutral” rating in a research note on Thursday, October 5th. Finally, Credit Suisse Group lowered shares of DENTSPLY SIRONA to a “hold” rating and set a $73.00 price objective for the company. in a research note on Friday, January 5th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and nine have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $69.15.

DENTSPLY SIRONA (NASDAQ:XRAY) traded down $3.00 during trading hours on Thursday, reaching $62.65. 5,304,700 shares of the company’s stock were exchanged, compared to its average volume of 2,594,300. The company has a market cap of $15,078.68, a price-to-earnings ratio of -18.05, a P/E/G ratio of 2.41 and a beta of 1.31. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.59 and a current ratio of 2.32. DENTSPLY SIRONA has a 1-year low of $52.53 and a 1-year high of $68.98.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings data on Friday, November 3rd. The medical instruments supplier reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.66 by $0.04. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $978.99 million. DENTSPLY SIRONA had a negative net margin of 20.33% and a positive return on equity of 7.56%. DENTSPLY SIRONA’s revenue was up 5.8% compared to the same quarter last year. During the same period last year, the business earned $0.66 EPS. sell-side analysts anticipate that DENTSPLY SIRONA will post 2.65 EPS for the current fiscal year.

In related news, Director Eric Brandt sold 6,409 shares of the firm’s stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $68.04, for a total value of $436,068.36. Following the transaction, the director now owns 12,073 shares of the company’s stock, valued at $821,446.92. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Francis J. Lunger sold 8,900 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $65.90, for a total transaction of $586,510.00. The disclosure for this sale can be found here. Insiders own 1.99% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of XRAY. Bessemer Group Inc. boosted its holdings in shares of DENTSPLY SIRONA by 4,638.6% in the third quarter. Bessemer Group Inc. now owns 1,903,596 shares of the medical instruments supplier’s stock worth $113,855,000 after buying an additional 1,863,424 shares during the last quarter. Alyeska Investment Group L.P. boosted its holdings in shares of DENTSPLY SIRONA by 223.7% in the third quarter. Alyeska Investment Group L.P. now owns 2,271,534 shares of the medical instruments supplier’s stock worth $135,860,000 after buying an additional 1,569,746 shares during the last quarter. Jackson Square Partners LLC boosted its holdings in shares of DENTSPLY SIRONA by 15.6% in the third quarter. Jackson Square Partners LLC now owns 6,334,906 shares of the medical instruments supplier’s stock worth $378,890,000 after buying an additional 855,199 shares during the last quarter. Parnassus Investments CA boosted its holdings in shares of DENTSPLY SIRONA by 62.7% in the third quarter. Parnassus Investments CA now owns 2,115,000 shares of the medical instruments supplier’s stock worth $126,498,000 after buying an additional 815,000 shares during the last quarter. Finally, Balyasny Asset Management LLC boosted its holdings in shares of DENTSPLY SIRONA by 415.5% in the second quarter. Balyasny Asset Management LLC now owns 800,937 shares of the medical instruments supplier’s stock worth $51,933,000 after buying an additional 645,564 shares during the last quarter. 96.13% of the stock is currently owned by institutional investors.

WARNING: “DENTSPLY SIRONA (XRAY) Earns “Hold” Rating from HC Wainwright” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/18/dentsply-sirona-xray-earns-hold-rating-from-hc-wainwright.html.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply